drugset / Trial / NCT06196294
GPC3/Mesothelin-CAR-γδT Cells Against Cancers
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The third generation of GPC3/mesothelin targeted CAR-γδT cells have been constructed and their anti-cancer function has been verified by multiple in vitro and in vivo studies. Clinical studies will be performed to test anti-cancer function of the CAR-γδT cells for immunotherapy of human cancer patients with GPC3 or Mesothelin expressions. In this phase I study, the safety, tolerance, and preliminary efficacy of the GPC3/Mesothelin-CAR-γδT cell immunotherapy on human cancers will firstly be evaluated.
Timeline
- Start
- 2024-05-10
- Primary completion
- 2030-11-30
- Completion
- 2036-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CAR-γδT cells | Cell therapy | — | Other |
| Subject | γδ T cells | Cell therapy | — | Other |